These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
469 related articles for article (PubMed ID: 31859138)
41. Ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome: Systematic review and meta-analysis. Misumida N; Aoi S; Kim SM; Ziada KM; Abdel-Latif A Cardiovasc Revasc Med; 2018 Sep; 19(6):689-694. PubMed ID: 29452843 [TBL] [Abstract][Full Text] [Related]
42. Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis. Wang Z; Zhou DY; Su Y; Si LY; Xu Q BMC Cardiovasc Disord; 2020 Mar; 20(1):130. PubMed ID: 32164560 [TBL] [Abstract][Full Text] [Related]
43. Comparison of 1-year clinical outcomes between prasugrel and ticagrelor versus clopidogrel in type 2 diabetes patients with acute myocardial infarction underwent successful percutaneous coronary intervention. Ahn KT; Seong SW; Choi UL; Jin SA; Kim JH; Lee JH; Choi SW; Jeong MH; Chae SC; Kim YJ; Kim CJ; Kim HS; Cho MC; Gwon HC; Jeong JO; Seong IW; Medicine (Baltimore); 2019 Mar; 98(11):e14833. PubMed ID: 30882670 [TBL] [Abstract][Full Text] [Related]
44. Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. Bergmark BA; Bhatt DL; Steg PG; Budaj A; Storey RF; Gurmu Y; Kuder JF; Im K; Magnani G; Oude Ophuis T; Hamm C; Špinar J; Kiss RG; Van de Werf FJ; Montalescot G; Johanson P; Braunwald E; Sabatine MS; Bonaca MP J Am Heart Assoc; 2021 Sep; 10(17):e020446. PubMed ID: 34423649 [TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of switching from ticagrelor to clopidogrel during the early and late phase in acute coronary syndrome patients after percutaneous coronary intervention. Wang C; Zheng W; Shaqdan A; Wang C; Qin X; Zhao X; Wang X; Yuan L; Nie S; Liu R Platelets; 2020; 31(3):337-343. PubMed ID: 31043110 [TBL] [Abstract][Full Text] [Related]
46. Frailty and Clinical Outcomes of Ticagrelor Versus Clopidogrel in Older Adults With Acute Myocardial Infarction. Ko D; Evans PT; Lin KJ; Pande AN; Cervone A; Lee SB; Cheng S; Tsacogianis T; Glynn RJ; Kim DH J Am Heart Assoc; 2024 Aug; 13(15):e034529. PubMed ID: 39056329 [TBL] [Abstract][Full Text] [Related]
47. Efficacy and Safety of Ticagrelor Compared with Clopidogrel in Patients with End-Stage Renal Disease with Acute Myocardial Infarction. Lee CH; Tsai TH; Lin CJ; Hsueh SK; Chung WJ; Cheng CI Am J Cardiovasc Drugs; 2019 Jun; 19(3):325-334. PubMed ID: 30746615 [TBL] [Abstract][Full Text] [Related]
48. Comparative Effectiveness and Safety of Ticagrelor and Clopidogrel in Patients With or Without Chronic Liver Disease: A Nationwide Cohort Study. Hong B; Bea S; You SC; Chang Y; Kim W; Shin JY Am J Med; 2024 Aug; 137(8):742-750.e11. PubMed ID: 38641192 [TBL] [Abstract][Full Text] [Related]
49. Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Tang X; Li R; Jing Q; Wang Q; Liu P; Zhang P; Liu Y J Cardiovasc Pharmacol; 2016 Aug; 68(2):115-20. PubMed ID: 27010809 [TBL] [Abstract][Full Text] [Related]
50. Prasugrel or ticagrelor in patients with acute coronary syndrome and diabetes: a propensity matched substudy of RENAMI. Conrotto F; Bertaina M; Raposeiras-Roubin S; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Flores Blanco P; Garay A; Quadri G; Varbella F; Caneiro Queija B; Cobas Paz R; Cespón Fernández M; Muñoz Pousa I; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Abu-Assi E; D'Ascenzo F Eur Heart J Acute Cardiovasc Care; 2019 Sep; 8(6):536-542. PubMed ID: 30270638 [TBL] [Abstract][Full Text] [Related]
51. Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry. Christ G; Siller-Matula JM; Francesconi M; Dechant C; Grohs K; Podczeck-Schweighofer A BMJ Open; 2014 Oct; 4(10):e005781. PubMed ID: 25361837 [TBL] [Abstract][Full Text] [Related]
52. Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial. Berwanger O; Nicolau JC; Carvalho AC; Jiang L; Goodman SG; Nicholls SJ; Parkhomenko A; Averkov O; Tajer C; Malaga G; Saraiva JFK; Fonseca FA; De Luca FA; Guimaraes HP; de Barros E Silva PGM; Damiani LP; Paisani DM; Lasagno CMR; Candido CT; Valeis N; Moia DDF; Piegas LS; Granger CB; White HD; Lopes RD; JAMA Cardiol; 2018 May; 3(5):391-399. PubMed ID: 29525822 [TBL] [Abstract][Full Text] [Related]
53. Ticagrelor or Clopidogrel as Antiplatelet Agents in Patients with Chronic Kidney Disease and Cardiovascular Disease: A Meta-analysis. Guo Y; Ge P; Li Z; Xiao J; Xie L Am J Cardiovasc Drugs; 2023 Sep; 23(5):533-546. PubMed ID: 37530990 [TBL] [Abstract][Full Text] [Related]
54. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. Baber U; Leisman DE; Cohen DJ; Gibson CM; Henry TD; Dangas G; Moliterno D; Kini A; Krucoff M; Colombo A; Chieffo A; Sartori S; Witzenbichler B; Steg PG; Pocock SJ; Mehran R Circ Cardiovasc Qual Outcomes; 2019 Jan; 12(1):e004945. PubMed ID: 30606052 [TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of ticagrelor versus clopidogrel in patients with non-ST-elevation myocardial infarction in Taiwan. Lee CK; Wang TD; Juang HT; Chang SC; Pan HY; Lin DS; Chang CJ Sci Rep; 2021 Jul; 11(1):14150. PubMed ID: 34239030 [TBL] [Abstract][Full Text] [Related]
56. Bleeding risk of ticagrelor compared to clopidogrel in intensive care unit patients with acute coronary syndrome: A propensity-score matching analysis. Charpentier T; Ferdynus C; Lair T; Cordier C; Brulliard C; Valance D; Emery M; Caron M; Allou N; Allyn J PLoS One; 2020; 15(5):e0232768. PubMed ID: 32365100 [TBL] [Abstract][Full Text] [Related]
57. The current status and outcomes of in-hospital P2Y12 receptor inhibitor switching in Korean patients with acute myocardial infarction. Park KH; Jeong MH; Kim HK; Ki YJ; Kim SS; Ahn Y; Kook HY; Kim HS; Gwon HC; Seung KB; Rha SW; Chae SC; Kim CJ; Cha KS; Park JS; Yoon JH; Chae JK; Joo SJ; Choi DJ; Hur SH; Seong IW; Cho MC; Kim DI; Oh SK; Ahn TH; Hwang JY; Korean J Intern Med; 2022 Mar; 37(2):350-365. PubMed ID: 35016269 [TBL] [Abstract][Full Text] [Related]
58. Comparison of the Effects of Ticagrelor and Clopidogrel on Microvascular Dysfunction in Patients With Acute Coronary Syndrome Using Invasive Physiologic Indices. Park K; Cho YR; Park JS; Park TH; Kim MH; Kim YD Circ Cardiovasc Interv; 2019 Oct; 12(10):e008105. PubMed ID: 31554423 [TBL] [Abstract][Full Text] [Related]
59. High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT. Zocca P; Kok MM; van der Heijden LC; van Houwelingen KG; Hartmann M; de Man FHAF; Stoel MG; Louwerenburg JHW; Knottnerus IL; Linssen GCM; Doggen CJM; von Birgelen C Int J Cardiol; 2018 Oct; 268():11-17. PubMed ID: 29801763 [TBL] [Abstract][Full Text] [Related]
60. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]